Evaluation of Strontium-Containing PCL-PDIPF Scaffolds for Bone Tissue Engineering: <i>In Vitro</i> and <i>In Vivo Studies</i>

Abstract

Bone tissue engineering (BTE) has the general objective of restoring and improving damaged bone. A very interesting strategy for BTE is to combine an adequate polymeric scaffold with an osteoinductive compound. Strontium is a divalent cation that can substitute calcium in hydroxyapatite and induce both anabolic and anti-catabolic effects in bone. On the other hand, systemic increases in Sr²⁺ levels can provoke adverse cardiovascular effects. In the present study we have developed a compatibilized blend of poly-ε-caprolactone (PCL) and polydiisopropyl fumarate (PDIPF) enriched with 1% or 5% Sr²⁺ and evaluated the applicability of these biomaterials for BTE, both <i>in vitro</i> and <i>in vivo</i>. <i>In vitro</i>, whereas Blend + 5% Sr²⁺ was pro-inflammatory and anti-osteogenic, Blend + 1% Sr²⁺ released very low quantities of the cation; was not cytotoxic for cultured macrophages; and showed improved osteocompatibility when used as a substratum for primary cultures of bone marrow stromal cells. <i>In vivo</i>, implants with Blend + 1% Sr²⁺ significantly increased bone tissue regeneration and improved fibrous bridging (vs. Blend alone), while neither inducing a local inflammatory response nor increased serum levels of Sr²⁺. These results indicate that our compatibilized blend of PCL-PDIPF enriched with 1% Sr²⁺ could be useful for BTE.